{"id":199926,"date":"2019-04-12T10:49:28","date_gmt":"2019-04-12T15:49:28","guid":{"rendered":"https:\/\/www.liveaction.org\/news\/?p=199926"},"modified":"2019-04-13T01:16:43","modified_gmt":"2019-04-13T06:16:43","slug":"prenatal-blood-testing-not-medical-guidelines","status":"publish","type":"post","link":"https:\/\/archive.liveaction.org\/news\/prenatal-blood-testing-not-medical-guidelines\/","title":{"rendered":"Study: Prenatal blood testing companies give parents ‘incomplete’ information"},"content":{"rendered":"
<\/div>

Not one single laboratory offering prenatal blood tests is following the recommended guidelines set by medical authorities, a new study has found<\/a>. Known as non-invasive prenatal testing, or NIPT, these tests are marketed as a way for expectant parents to find out if there are any medical issues with their babies, such as Down syndrome. But while these tests are meant to be used only as a screening tool, they are instead being advertised as diagnostic — and leading parents to make decisions based on potentially inaccurate information.\u00a0But instead of being told of the likelihood that their child has a medical condition, and being given the percentage the labs estimated, parents are instead merely being told that the tests are positive or negative for the condition.<\/p>\n

The study, authored by Dr. Brian Skotko, has been published in the peer-review journal “Genetics in Medicine,” the official journal of the American College of Medical Genetics and Genomics (ACMG). \u201cIt\u2019s been more than two years since the ACMG published its recommendations about NIPS, and we could not find a single commercial lab in the U.S. that adhered to all of the recommendations,\u201d Dr. Skotko explained in a press release. “Incomplete or inaccurate reporting can lead to confusion and improper counseling. The ACMG was clear that laboratories should not offer screening when some of their recommendations were not met, so I think our findings will be concerning to clinicians and expectant parents trying to identify quality NIPS reporting in today\u2019s marketplace.\u201d<\/p>\n

One important factor is how NIPTs work. From the blood taken from the mother, the labs will examine DNA, looking for fragments of chromosomes. If there are more than typically expected, the lab will make an estimated guess, using a percentage, of whether or not the baby has a condition such as Down syndrome. But this is simply a guess<\/em>, not a diagnosis. “ACMG was clear from the beginning that this was a screening test, not a diagnostic one,” Dr. Skotko told Reuters<\/a>.<\/p>\n

READ:\u00a0Parents of autistic children: Prenatal autism test will lead to more abortion<\/a><\/em><\/strong><\/p>\n